SearchSearach Website
Close Searach

Search Website

A

Larger Smaller

A

Living Well With Low Vision Sponsored by Prevent Blindness
  • News
  • Clinical Trials
  • Resources
  • Free Books
  • Stories
  • About
  • Contact
  • Donate
Skip to content
Skip to content

Living Well With Low Vision

  • News
  • Clinical Trials
  • Resources
  • Free Books
  • Stories
  • About
  • Contact
  • Donate

News & Archive Categories

    Month: November 2017

    Regeneron Study of Nesvacumab Discontinued

    Posted on November 27, 2017 by droberts
  • November 27, 2017

    Regeneron Study of Nesvacumab Discontinued

    It was recently reported here that nesvacumab (REGN910) was being tested in combination with Eylea (Regeneron) as a potential treatment for wet AMD. Regeneron, however, reported on November 27 that the results “did not provide sufficient differentiation to warrant Phase 3 development.” The Phase 2 trials have, therefore, been discontinued, and research data will be […]

      Also posted in
    • Latest News
    • Research and Developments
  • Two New Antiangiogenic Drugs Under Study for Wet AMD and DME

    Posted on November 20, 2017 by droberts
  • November 20, 2017

    Two New Antiangiogenic Drugs Under Study for Wet AMD and DME

    Since 2005, anti-VEGF drug injections have proved effective for treatment of neovascularization* secondary to age-related macular degeneration (AMD) and diabetic macular edema (DME). Several newer anti-VEGF therapies are also under study, including PAN-90806, OPT-302, ICON-1, RGX-314, and RTH258. All of these are described and sourced on this site. Recently, scientists have researched a possible counterpart […]

      Also posted in
    • Latest News
    • Research and Developments
  • Incidence of AMD Dramatically Declining

    Posted on November 18, 2017May 30, 2020 by droberts
  • November 18, 2017

    Incidence of AMD Dramatically Declining

    A recent observational study at the University of Wisconsin-Madison has found that the risk of developing age-related macular degeneration (AMD) has been dramatically lessening over three generations. After looking at follow-up data on 4,819 participants and their offspring in the Beaver Dam studies (1987-2013), Karen J. Cruickshanks, Ph.D. et al found that the incidence of […]

      Also posted in
    • Latest News
    • Research and Developments
  • Two Trials Take First Step Toward Stem Cell Treatment for AMD

    Posted on November 16, 2017 by droberts
  • November 16, 2017

    Two Trials Take First Step Toward Stem Cell Treatment for AMD

    Results from two new clinical trials have added support for the use of human embryonic stem cells as treatment for the dry form of macular degeneration. Stem cells injected into the eye appear to have replaced the missing cells damaged by the disease, with no serious side effects. One study suggests it may have even improved patients’ […]

      Also posted in
    • Latest News
    • Research and Developments
  • Seeing AI Now Available Outside of U.S.

    Posted on November 16, 2017 by droberts
  • November 16, 2017

    Seeing AI Now Available Outside of U.S.

    We announced here in July that Microsoft had released Seeing AI,  a free app that harnesses the power of Artificial Intelligence (AI) to audibly read text, identify objects, and describe people. The app was originally available only in the United States, but it is now also in the British, Irish and Australian App stores. It is still available only for iOS devices […]

      Also posted in
    • Latest News
  • Brolucizimab May Be the Next Treatment Option for Wet AMD

    Posted on November 11, 2017September 27, 2019 by droberts
  • November 11, 2017

    Brolucizimab May Be the Next Treatment Option for Wet AMD

    (Updated 9/26/19) Swiss drugmaker Novartis has announced that their new anti-VEGF drug, brolucizumab (RTH258), is meeting expectations as a potentially more effective and longer lasting treatment for wet macular degeneration than at least one of the current options. Positive results from two Phase III studies of brolucizumab versus aflibercept (Eylea) were presented at the American […]

      Also posted in
    • Latest News
    • Research and Developments
Some Like it Neat, by Alex Vasquez
© All Rights Reserved
Footer Content Right

Receive News and Updates


 

We look to your generosity to support Prevent Blindness and keep our resources up to date.

Donate Now
  • Facebook
  • Twitter
Privacy Policy
Prevent Blindness

© 2018 Prevent Blindness. All rights reserved.